The new Swiss CDMO offering phase-adjusted CMC expertise at an attractive cost

Finding the right partner for First in Human production can be challenging.

ENABLE BIOTECH IS THE RIGHT PARTNER

We address specific challenges of manufacturing advanced therapies.

Learn more about how ENABLE BioTech can become YOUR next generation CDMO.

Service Offerings for Cell & Gene Therapy

Production of Cell Therapies, Gene-Modified Cell Therapies, and Exosome Therapies

Utilizing various cell types including PBMC (T Cells, NK cells, Invariant NK Cells) iPSC, MSC, HLSC, and more

Gene editing using viral vectors (AAV, LVV) or electroporation

Preparation of CMC sections in regulatory submissions, anticipating increasing clinical development requirements

Value Proposition

Focusing only on the needs of clinical stage companies pursuing a phase-adapted approach towards compliance, Enable Biotech has established an innovative setup for development and clinical manufacturing capacity, capabilities, and resources enabling a very attractive pricing structure.


With its network and team of highly qualified experts in the field that support special activities (RA, QP, QA (beyond normal routine), CMC, Engineering) ad hoc on demand to reduce basic operation costs while keeping access to their valuable knowledge, Enable Biotech is best positioned to ensure project realization that incorporates closely the project sponsor while providing guidance and making the wealth of existing experience available / accessible.

Infrastructure

Premises

Key Equipment

About Us

Enable Biotech Ltd, founded in 2023 in Zug, Switzerland, is offering innovative custom fee for service activities in the development and clinical manufacturing of Cell & Gene Therapies (ATMPs) and Exosome Therapies. As part of its service offering, Enable Biotech offers clinical GMP mancufacturing activities for Cell Therapies and Exosome Therapies and as of Summer 2024 clinical GMP manufacturing activities for Gene Therapies (awaiting accreditation by SwissMedic).

Alain Pralong

Chief Executive Officer

PhD in Molecular & Cell Biology

Yves Maag

Chief Operating Officer

Renaud Jacquemart

Chief Commercial Officer

MBA, PhD in Chemical Engineering

News

News

ENABLE Biotech Next-Generation ATMP CDMO Capacity Update

ENABLE Biotech’s focus is on providing start-up and spin-out companies in the advanced therapy space with a partner to support their unique challenges when it comes to preparing for early-stage clinical development. The team brings specific expertise and capabilities in process development and manufacturing ensuring a smooth transition into early-stage clinical testing.

read more »
News

Advanced Therapy Manufacturing for Start-Ups: The Need for a Next Generation CDMO

The cell and gene therapy sector is booming, with over 90 new trials in 2023 and nearly 4,000 treatments in progress. Small biotechs, often university spin-offs, are driving innovation but lack the resources for in-house manufacturing, leading 75% to partner with CDMOs. Yet, these start-ups have specific early-stage development needs not fully met by current CDMOs, necessitating a new model that offers tailored expertise and flexible pricing to support their unique challenges in this rapidly evolving field.

read more »

Contact

Enable Biotech Ltd.
Baarerstrasse 8
6300 Zug

Mail: contact@enablebiotech.ch
Tel: +41 41 244 06 66

By sending us an inquiry using our contact form or by email, you acknowledge and agree that we will store your request and your contact details provided to us for the purpose of contacting you and/or dealing with your inquiry and any subsequent matters. For further information, please consult our Privacy Policy.